Agomab Therapeutics, a biotech company developing small molecule inhibitors of ALK5 for fibrotic diseases, has announced a US$89m Series D financing round, with participation from new investors Sanofi and Invus,…
Agomab Therapeutics, a biotech company developing small molecule inhibitors of ALK5 for fibrotic diseases, has announced a US$89m Series D financing round, with participation from new investors Sanofi and Invus,…
…
…